- Home
- BWB vs PROK Comparison
BWB vs PROK Comparison
Compare BWB & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BWB
- PROK
- Stock Information
- Founded
- BWB 2005
- PROK 2015
- Country
- BWB United States
- PROK United States
- Employees
- BWB N/A
- PROK N/A
- Industry
- BWB Major Banks
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BWB Finance
- PROK Health Care
- Exchange
- BWB Nasdaq
- PROK Nasdaq
- Market Cap
- BWB 442.3M
- PROK 384.2M
- IPO Year
- BWB 2018
- PROK N/A
- Fundamental
- Price
- BWB $16.50
- PROK $2.41
- Analyst Decision
- BWB Strong Buy
- PROK Buy
- Analyst Count
- BWB 2
- PROK 5
- Target Price
- BWB $20.00
- PROK $6.25
- AVG Volume (30 Days)
- BWB 56.7K
- PROK 2.5M
- Earning Date
- BWB 07-23-2025
- PROK 08-12-2025
- Dividend Yield
- BWB N/A
- PROK N/A
- EPS Growth
- BWB 12.01
- PROK N/A
- EPS
- BWB 1.21
- PROK N/A
- Revenue
- BWB $119,312,000.00
- PROK $527,000.00
- Revenue This Year
- BWB $32.24
- PROK $105.79
- Revenue Next Year
- BWB $11.45
- PROK N/A
- P/E Ratio
- BWB $13.63
- PROK N/A
- Revenue Growth
- BWB 12.23
- PROK N/A
- 52 Week Low
- BWB $11.93
- PROK $0.46
- 52 Week High
- BWB $17.66
- PROK $7.13
- Technical
- Relative Strength Index (RSI)
- BWB 61.61
- PROK 47.47
- Support Level
- BWB $15.43
- PROK $2.22
- Resistance Level
- BWB $16.07
- PROK $2.59
- Average True Range (ATR)
- BWB 0.42
- PROK 0.25
- MACD
- BWB 0.06
- PROK -0.07
- Stochastic Oscillator
- BWB 98.16
- PROK 22.03
About BWB Bridgewater Bancshares Inc.
Bridgewater Bancshares Inc is a financial holding company. Through its subsidiary, it offers various personal and commercial banking products and services such as savings accounts, certificates of deposits, money transfer services, digital wallets, credit and debit cards, safe deposit lockers, different types of loans and advances, commercial deposit accounts, treasury management, and others. The company principally focuses on catering to commercial clients, offering them a suite of loan and deposit products. Geographically, it mainly operates in the Twin Cities Metropolitan Statistical Area in the United States.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.